Biotech stocks are going wild, and these two could be your best bet for a bigger breakout

div > div.group > p:first-child"> The IBB biotechnology ETF is on track for its best quarter in six years, adding 19 percent in a rally twice as steep as the gains on the XLV health care ETF.

"For a lot of investors, they're trying to play catch-up at this point in time, and they're going to continue to play these risk assets," Johnson said Friday on CNBC's"Trading Nation.""We still see decent upside from here to go — perhaps about 6 percent higher from here, maybe as high as 13 percent higher.""One of the names that looks pretty good to us is Regeneron," Johnson said.

John Petrides, portfolio manager at Point View Wealth Manager, has a different pick for biotech stock ready to race higher.

Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen

Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.

Lyft is using a controversial new stock structure in its IPO that will let its founders keep 'significant control' of the companyOne share for one vote is no longer the case among tech unicorns who go public.
Herkunft: BusinessInsider - 🏆 729. / 51 Weiterlesen »